PARENTERAL MEDROXYPROGESTERONE FOR THE MANAGEMENT OF LUTEINIZING HORMONE RELEASING HORMONE INDUCED HOT FLASHES IN MEN WITH ADVANCED PROSTATE CANCER

This study is the first multi-institutional evaluation of hot flashes demonstrating significant reduction in quantity and severity with MPA. Based on these data we now manage hot flashes associated with LHRH analogues with 400 mg of MPA.